Nature Communications (Jun 2021)
Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action
- Florian Kast,
- Martin Schwill,
- Jakob C. Stüber,
- Svende Pfundstein,
- Gabriela Nagy-Davidescu,
- Josep M. Monné Rodríguez,
- Frauke Seehusen,
- Christian P. Richter,
- Annemarie Honegger,
- Karen Patricia Hartmann,
- Thomas G. Weber,
- Felix Kroener,
- Patrick Ernst,
- Jacob Piehler,
- Andreas Plückthun
Affiliations
- Florian Kast
- Department of Biochemistry, University of Zurich
- Martin Schwill
- Department of Biochemistry, University of Zurich
- Jakob C. Stüber
- Department of Biochemistry, University of Zurich
- Svende Pfundstein
- Department of Biochemistry, University of Zurich
- Gabriela Nagy-Davidescu
- Department of Biochemistry, University of Zurich
- Josep M. Monné Rodríguez
- Laboratory for Animal Model Pathology, Institute of Veterinary Pathology, Vetsuisse Faculty, University of Zurich
- Frauke Seehusen
- Laboratory for Animal Model Pathology, Institute of Veterinary Pathology, Vetsuisse Faculty, University of Zurich
- Christian P. Richter
- Department of Biology/Chemistry and Center for Cellular Nanoanalytics, Osnabrück University
- Annemarie Honegger
- Department of Biochemistry, University of Zurich
- Karen Patricia Hartmann
- Department of Biochemistry, University of Zurich
- Thomas G. Weber
- Dynamic Biosensors GmbH
- Felix Kroener
- Dynamic Biosensors GmbH
- Patrick Ernst
- Department of Biochemistry, University of Zurich
- Jacob Piehler
- Department of Biology/Chemistry and Center for Cellular Nanoanalytics, Osnabrück University
- Andreas Plückthun
- Department of Biochemistry, University of Zurich
- DOI
- https://doi.org/10.1038/s41467-021-23948-6
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 18
Abstract
HER2 acts an oncogenic driver in numerous cancers. Here, the authors design an anti-HER2 biparatopic and tetravalent IgG fusion with inhibitory effects in a xenograft model.
